These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29589830)

  • 1. Transmission genetics of drug-resistant hepatitis C virus.
    van Buuren N; Tellinghuisen TL; Richardson CD; Kirkegaard K
    Elife; 2018 Mar; 7():. PubMed ID: 29589830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding.
    Issur M; Götte M
    Viruses; 2014 Nov; 6(11):4227-41. PubMed ID: 25384189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy.
    Abdel-Hameed EA; Rouster SD; Ji H; Ulm A; Hetta HF; Anwar N; Sherman KE; Shata MT
    Viral Immunol; 2016 May; 29(4):252-8. PubMed ID: 26885675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China.
    Nie B; Guo Y; Zhang K; Liu J; Yun S
    Arch Virol; 2020 Sep; 165(9):2013-2020. PubMed ID: 32601956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir.
    Susser S; Flinders M; Reesink HW; Zeuzem S; Lawyer G; Ghys A; Van Eygen V; Witek J; De Meyer S; Sarrazin C
    Antimicrob Agents Chemother; 2015 May; 59(5):2746-55. PubMed ID: 25712364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of whole genome sequencing in the Dutch Acute HCV in HIV study: focus on transmitted antiviral resistance.
    Christiansen MT; Hullegie SJ; Schutten M; Einer-Jensen K; Tutill HJ; Breuer J; Rijnders BJA
    Clin Microbiol Infect; 2017 Feb; 23(2):123.e1-123.e4. PubMed ID: 27693529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
    McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
    J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral resistance and direct-acting antiviral agents for HCV.
    Aloia AL; Locarnini S; Beard MR
    Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced fitness of hepatitis C virus increases resistance to direct-acting antivirals.
    Soni S; Singh D; Aggarwal R; Veerapu NS
    J Gen Virol; 2022 Feb; 103(2):. PubMed ID: 35133954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
    Franco S; Bellido R; Aparicio E; Cañete N; García-Retortillo M; Solà R; Tural C; Clotet B; Paredes R; Martínez MA
    J Viral Hepat; 2011 Oct; 18(10):e578-82. PubMed ID: 21914079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-acting and host-targeting HCV inhibitors: current and future directions.
    Chatel-Chaix L; Germain MA; Götte M; Lamarre D
    Curr Opin Virol; 2012 Oct; 2(5):588-98. PubMed ID: 22959589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays.
    Verbinnen T; Jacobs T; Vijgen L; Ceulemans H; Neyts J; Fanning G; Lenz O
    J Antimicrob Chemother; 2012 Oct; 67(10):2327-37. PubMed ID: 22723600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus.
    Gallego I; Sheldon J; Moreno E; Gregori J; Quer J; Esteban JI; Rice CM; Domingo E; Perales C
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3786-93. PubMed ID: 27067341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
    Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
    Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current race in the development of DAAs (direct-acting antivirals) against HCV.
    De Clercq E
    Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank.
    Kliemann DA; Tovo CV; Gorini da Veiga AB; Machado AL; West J
    PLoS One; 2016; 11(8):e0159924. PubMed ID: 27504952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals.
    Ahmed A; Felmlee DJ
    Viruses; 2015 Dec; 7(12):6716-29. PubMed ID: 26694454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virologic Tools for HCV Drug Resistance Testing.
    Fourati S; Pawlotsky JM
    Viruses; 2015 Dec; 7(12):6346-59. PubMed ID: 26690198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.